Target intelligence / Profile preview

MicroRNA-1205 (miR-1205)

Target
miR-1205
Molecular classification
Non-coding RNA, MicroRNA (miRNA), Regulatory RNA, Other
01

Overview

MicroRNA-1205 (miR-1205) is a small, non-coding regulatory RNA encoded by the PVT1 locus at chromosome 8q24 and acts post-transcriptionally to regulate gene expression by binding to complementary sequences on target mRNAs, leading to their degradation or translation inhibition. miR-1205 is underexpressed in several human cancers, including prostate cancer and laryngeal squamous cell carcinoma, and acts as a tumor suppressor by directly targeting and inhibiting oncogenic mRNAs such as FRYL and E2F1. Functionally, overexpression of miR-1205 can induce apoptosis, suppress tumor growth, and inhibit cancer cell migration and invasion, with evidence suggesting involvement in neural pathways and neuroendocrine differentiation. Its expression levels have been associated with disease progression and prognosis, and mimics of miR-1205 are in preclinical development as a potential therapeutic strategy in oncology.

Other names
hsa-miR-1205MIR1205MIRN1205hsa-mir-1205
02

Mechanism of action

Synthetic miR-1205 mimic: restores/increases miR-1205 levels to induce apoptosis and tumor suppression in cancer cells by targeting downstream mRNAs such as FRYL and E2F1

03

Biological functions

Post-transcriptional gene regulationInduction of apoptosisSuppression of cell migration and invasionRegulation of neuroendocrine differentiationInvolvement in neural-associated pathways (e.g., dendrite regulation, cell differentiation)
04

Disease associations

Cancer (notably prostate cancer and laryngeal squamous cell carcinoma)Tumor suppression (in aggressive prostate cancer)Prognostic association in laryngeal squamous cell carcinoma
05

Safety considerations

As an experimental RNA-based therapy, possible challenges include delivery specificity, off-target gene regulation, and immune-related adverse effectsNo clinical safety concerns reported yet; research is preclinical
06

Interacting drugs

NB1205 (experimental synthetic miR-1205 mimic/analogue)

1 more in the full profile.

07

Biomarkers

miR-1205 expression levels (may serve as biomarker for prostate cancer and laryngeal squamous cell carcinoma for diagnosis, prognosis, or patient stratification)Possibly levels of downstream targets such as FRYL and E2F1 in relevant cancer tissues

Beyond the preview

Go deeper on MicroRNA-1205 (miR-1205).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA-1205 (miR-1205).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call